Ruyi Shi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ruyi Shi has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- Chongwei Chen
Shanxi Key Lab of Bone and Soft Tissue Injury Repair, Department of Orthopaedics, The Second Hospital of Shanxi Medical University, Taiyuan, 030001, China
2 shared publications Diyu Wang
Department of Cell Biology and Medical Genetics, School of Basic Medical Sciences, Shanxi Medical University, Taiyuan, 030001, China
2 shared publications- Genlai Du
Department of Cell Biology and Medical Genetics, School of Basic Medical Sciences, Shanxi Medical University, Taiyuan, 030001, China
2 shared publications Jiaru Sun
Department of Cell Biology and Medical Genetics, School of Basic Medical Sciences, Shanxi Medical University, Taiyuan, 030001, China
2 shared publications- Qin Zhang
Department of Orthopedics, Yuncheng Central Hospital Affiliated to Shanxi Medical University
2 shared publications Qingqian Chen
Department of Cell Biology and Medical Genetics, School of Basic Medical Sciences, Shanxi Medical University, Taiyuan, 030001, China
2 shared publications
Latest Publications
- 22 August 2026
- Published by Elsevier in Materials Science and Engineering: C
- Vol. 189, 215130
A stiffness-tunable 3D alginate-collagen-hyaluronic acid model reveals the matrix-dependent chondroprotection of quercetin in osteoarthritis
- 22 August 2026
- Published by Elsevier in Materials Science and Engineering: C
- Vol. 189, 215130
A stiffness-tunable 3D alginate-collagen-hyaluronic acid model reveals the matrix-dependent chondroprotection of quercetin in osteoarthritis
- 19 January 2026
- Published by Elsevier in Acta Histochemica
- Vol. 128 (2) , 152323
Stiffness-tunable alginate-hyaluronic acid-collagen hydrogel mimics chondrocyte microenvironment for osteoarthritis pathophysiological modeling
- 19 January 2026
- Published by Elsevier in Acta Histochemica
- Vol. 128 (2) , 152323
Stiffness-tunable alginate-hyaluronic acid-collagen hydrogel mimics chondrocyte microenvironment for osteoarthritis pathophysiological modeling
- Open Access
- 3 September 2020
- Published by Innovation Publishing House Pte. Ltd. in STEMedicine
- Vol. 1 (4) , e57
Osteoclast biology in bone resorption: a review
What we know about bone resorption has changed a lot in the last few decades. The osteoclast is the only cell to nibble and break down the bone, and in the formation and resorption of bone tissue, osteoclasts play an important role. Once the balance of bone formation and bone loss is out of control, diseases like osteopetrosis and osteoporosis occur. Bone resorption is a unique function of osteoblasts, which are multinucleated cells formed by the fusion of mononuclear progenitor cells of the monocyte/macrophage family. In the formation of osteoclasts, there are two main factors affecting this process, macrophage colony-stimulating factor (M-CSF) and ligand-activated receptor (RANKL) of nuclear factor kappa B (NF-κB). The identification of RANK-RANKL signaling and other classic signaling pathways such as Wnt and Notch, as the major signaling regulation in osteoclast differentiation, was a significant breakthrough in the field of osteoclastogenesis. In this review, we briefly describe the latest knowledge of osteoclast-induced bone resorption and cellular factors that regulate the activity of osteoclasts and cell fusion, for the purpose of understanding osteoclastogenesis and the development of drugs that enhance bone resorption to improve pathological bone diseases.
- 3 September 2020
- Published by Innovation Publishing House Pte. Ltd. in STEMedicine
- Vol. 1 (4) , e57
Open AccessOsteoclast biology in bone resorption: a review
What we know about bone resorption has changed a lot in the last few decades. The osteoclast is the only cell to nibble and break down the bone, and in the formation and resorption of bone tissue, osteoclasts play an important role. Once the balance of bone formation and bone loss is out of control, diseases like osteopetrosis and osteoporosis occur. Bone resorption is a unique function of osteoblasts, which are multinucleated cells formed by the fusion of mononuclear progenitor cells of the monocyte/macrophage family. In the formation of osteoclasts, there are two main factors affecting this process, macrophage colony-stimulating factor (M-CSF) and ligand-activated receptor (RANKL) of nuclear factor kappa B (NF-κB). The identification of RANK-RANKL signaling and other classic signaling pathways such as Wnt and Notch, as the major signaling regulation in osteoclast differentiation, was a significant breakthrough in the field of osteoclastogenesis. In this review, we briefly describe the latest knowledge of osteoclast-induced bone resorption and cellular factors that regulate the activity of osteoclasts and cell fusion, for the purpose of understanding osteoclastogenesis and the development of drugs that enhance bone resorption to improve pathological bone diseases.
- Open Access
- 18 July 2018
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 9 (1) , 200
Previously claimed male germline stem cells from porcine testis are actually progenitor Leydig cells
Male germline stem cells (mGSCs) offer great promise in regenerative medicine and animal breeding due to their capacity to maintain self-renewal and to transmit genetic information to the next generation following spermatogenesis. Human testis-derived embryonic stem cell-like cells have been shown to possess potential of mesenchymal progenitors, but there remains confusion about the characteristics and origin of porcine testis-derived stem cells. Porcine testis-derived stem cells were obtained from primary testicular cultures of 5-day old piglets, and selectively expanded using culture conditions for long-term culture and induction differentiation. The stem cell properties of porcine testis-derived stem cells were subsequently assessed by determining the expression of pluripotency-associated markers, alkaline phosphatase (AP) activity, and capacity for sperm and multilineage differentiation in vitro. The gene expression profile was compared via microarray analysis. We identified two different types of testis-derived stem cells (termed as C1 and C2 here) during porcine testicular cell culture. The gene expression microarray analysis showed that the transcriptome profile of C1 and C2 differed significantly from each other. The C1 appeared to be morphologically similar to the previously described mouse mGSCs, expressed pluripotency- and germ cell-associated markers, maintained the paternal imprinted pattern of H19, displayed alkaline phosphatase activity, and could differentiate into sperm. Together, these data suggest that C1 represent the porcine mGSC population. Conversely, the C2 appeared similar to the previously described porcine mGSCs with three-dimensional morphology, abundantly expressed Leydig cell lineage and mesenchymal cell-specific markers, and could differentiate into testosterone-producing Leydig cells, suggesting that they are progenitor Leydig cells (PLCs). Collectively, we have established the expected characteristics and markers of authentic porcine mGSCs (C1). We found for the first time that, the C2, equivalent to previously claimed porcine mGSCs, are actually progenitor Leydig cells (PLCs). These findings provide new insights into the discrepancies among previous reports and future identification and analyses of testis-derived stem cells.
- 18 July 2018
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 9 (1) , 200
Open AccessPreviously claimed male germline stem cells from porcine testis are actually progenitor Leydig cells
Male germline stem cells (mGSCs) offer great promise in regenerative medicine and animal breeding due to their capacity to maintain self-renewal and to transmit genetic information to the next generation following spermatogenesis. Human testis-derived embryonic stem cell-like cells have been shown to possess potential of mesenchymal progenitors, but there remains confusion about the characteristics and origin of porcine testis-derived stem cells. Porcine testis-derived stem cells were obtained from primary testicular cultures of 5-day old piglets, and selectively expanded using culture conditions for long-term culture and induction differentiation. The stem cell properties of porcine testis-derived stem cells were subsequently assessed by determining the expression of pluripotency-associated markers, alkaline phosphatase (AP) activity, and capacity for sperm and multilineage differentiation in vitro. The gene expression profile was compared via microarray analysis. We identified two different types of testis-derived stem cells (termed as C1 and C2 here) during porcine testicular cell culture. The gene expression microarray analysis showed that the transcriptome profile of C1 and C2 differed significantly from each other. The C1 appeared to be morphologically similar to the previously described mouse mGSCs, expressed pluripotency- and germ cell-associated markers, maintained the paternal imprinted pattern of H19, displayed alkaline phosphatase activity, and could differentiate into sperm. Together, these data suggest that C1 represent the porcine mGSC population. Conversely, the C2 appeared similar to the previously described porcine mGSCs with three-dimensional morphology, abundantly expressed Leydig cell lineage and mesenchymal cell-specific markers, and could differentiate into testosterone-producing Leydig cells, suggesting that they are progenitor Leydig cells (PLCs). Collectively, we have established the expected characteristics and markers of authentic porcine mGSCs (C1). We found for the first time that, the C2, equivalent to previously claimed porcine mGSCs, are actually progenitor Leydig cells (PLCs). These findings provide new insights into the discrepancies among previous reports and future identification and analyses of testis-derived stem cells.
- Open Access
- 11 January 2016
- Published by Oxford University Press (OUP) in GigaScience
- Vol. 5 (1) , 1
Genomic analyses reveal FAM84B and the NOTCH pathway are associated with the progression of esophageal squamous cell carcinoma
Background: Esophageal squamous cell carcinoma (ESCC) is the sixth most lethal cancer worldwide and the fourth most lethal cancer in China. Genomic characterization of tumors, particularly those of different stages, is likely to reveal additional oncogenic mechanisms. Although copy number alterations and somatic point mutations associated with the development of ESCC have been identified by array-based technologies and genome-wide studies, the genomic characterization of ESCCs from different stages of the disease has not been explored. Here, we have performed either whole-genome sequencing or whole-exome sequencing on 51 stage I and 53 stage III ESCC patients to characterize the genomic alterations that occur during the various clinical stages of ESCC, and further validated these changes in 36 atypical hyperplasia samples. Results: Recurrent somatic amplifications at 8q were found to be enriched in stage I tumors and the deletions of 4p-q and 5q were particularly identified in stage III tumors. In particular, the FAM84B gene was amplified and overexpressed in preclinical and ESCC tumors. Knockdown of FAM84B in ESCC cell lines significantly reduced in vitro cell growth, migration and invasion. Although the cancer-associated genes TP53, PIK3CA, CDKN2A and their pathways showed no significant difference between stage I and stage III tumors, we identified and validated a prevalence of mutations in NOTCH1 and in the NOTCH pathway that indicate that they are involved in the preclinical and early stages of ESCC. Conclusions: Our results suggest that FAM84B and the NOTCH pathway are involved in the progression of ESCC and may be potential diagnostic targets for ESCC susceptibility.
- 11 January 2016
- Published by Oxford University Press (OUP) in GigaScience
- Vol. 5 (1) , 1
Open AccessGenomic analyses reveal FAM84B and the NOTCH pathway are associated with the progression of esophageal squamous cell carcinoma
Background: Esophageal squamous cell carcinoma (ESCC) is the sixth most lethal cancer worldwide and the fourth most lethal cancer in China. Genomic characterization of tumors, particularly those of different stages, is likely to reveal additional oncogenic mechanisms. Although copy number alterations and somatic point mutations associated with the development of ESCC have been identified by array-based technologies and genome-wide studies, the genomic characterization of ESCCs from different stages of the disease has not been explored. Here, we have performed either whole-genome sequencing or whole-exome sequencing on 51 stage I and 53 stage III ESCC patients to characterize the genomic alterations that occur during the various clinical stages of ESCC, and further validated these changes in 36 atypical hyperplasia samples. Results: Recurrent somatic amplifications at 8q were found to be enriched in stage I tumors and the deletions of 4p-q and 5q were particularly identified in stage III tumors. In particular, the FAM84B gene was amplified and overexpressed in preclinical and ESCC tumors. Knockdown of FAM84B in ESCC cell lines significantly reduced in vitro cell growth, migration and invasion. Although the cancer-associated genes TP53, PIK3CA, CDKN2A and their pathways showed no significant difference between stage I and stage III tumors, we identified and validated a prevalence of mutations in NOTCH1 and in the NOTCH pathway that indicate that they are involved in the preclinical and early stages of ESCC. Conclusions: Our results suggest that FAM84B and the NOTCH pathway are involved in the progression of ESCC and may be potential diagnostic targets for ESCC susceptibility.